DSGN — Design Therapeutics Share Price
0.000.00%
Last trade - 00:00- $209.03m
- -$72.77m
- 37
- 40
- 60
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | 0.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.92% | ||
| Return on Equity | -22.1% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.83 | 0.23 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Directors
- Pratik Shah CHM
- Joao Siffert PRE (57)
- Aseem Ansari CFD
- Sean Jeffries COO (41)
- Julie Burgess CAO (52)
- Dawn Giangiulio CTR
- Jae Kim OTH (52)
- Heather Behanna DRC
- Deepa Prasad DRC (41)
- Simeon George IND
- Rodney Lappe IND (66)
- John Schmid IND (58)
- Arsani William IND (32)
- Stella Xu IND (50)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 18th, 2017
- Public Since
- March 26th, 2021
- No. of Shareholders
- 13
- No. of Employees
- 58
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 56,494,271
- Address
- 6005 Hidden Valley Road, Suite 110, CARLSBAD, 92011
- Web
- https://www.designtx.com/
- Phone
- +1 8582934900
- Auditors
- Ernst & Young LLP
Upcoming Events for DSGN
Q2 2024 Design Therapeutics Inc Earnings Release
Similar to DSGN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Design Therapeutics share price?
As of Today at 19:06 UTC, shares in Design Therapeutics are trading at $3.70. This share price information is delayed by 15 minutes.
How has the Design Therapeutics share price performed this year?
Shares in Design Therapeutics last closed at $3.70 and the price had moved by -33.81% over the past 365 days. In terms of relative price strength the Design Therapeutics share price has underperformed the S&P500 Index by -44.92% over the past year.
What are the analyst and broker recommendations for Design Therapeutics?
The overall consensus recommendation for Design Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Design Therapeutics dividend yield?
Design Therapeutics does not currently pay a dividend.
Does Design Therapeutics pay a dividend?
Design Therapeutics does not currently pay a dividend.
When does Design Therapeutics next pay dividends?
Design Therapeutics does not currently pay a dividend.
How do I buy Design Therapeutics shares?
To buy shares in Design Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Design Therapeutics?
As of the previous close price of $3.70, shares in Design Therapeutics had a market capitalisation of $209.03m.
Where are Design Therapeutics shares listed?
Here are the trading details for Design Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DSGN
What kind of share is Design Therapeutics?
Based on an overall assessment of its quality, value and momentum Design Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Design Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Design Therapeutics is $4.75. That is 28.38% above the last closing price of $3.70.
Analysts covering Design Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.18 for the next financial year.
What is the trend in the Design Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Design Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +46.1%.
As of the last closing price of $3.70, shares in Design Therapeutics were trading +14.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Design Therapeutics PE Ratio?
The Design Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Design Therapeutics?
Design Therapeutics' management team is headed by:
- Pratik Shah - CHM
- Joao Siffert - PRE
- Aseem Ansari - CFD
- Sean Jeffries - COO
- Julie Burgess - CAO
- Dawn Giangiulio - CTR
- Jae Kim - OTH
- Heather Behanna - DRC
- Deepa Prasad - DRC
- Simeon George - IND
- Rodney Lappe - IND
- John Schmid - IND
- Arsani William - IND
- Stella Xu - IND